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1 Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil,
2 Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, United States of
America, 3 Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium, 4 Department
of Experimental, Diagnostic and Specialty Medicine-DIMES, Bologna University Hospital, Bologna, Italy,
5 Medical Clinic II/V, University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany,
6 Department of Medicine, Imperial College London, London, United Kingdom, 7 Clinical Department of
Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague,
Czech Republic, 8 Department of Biostatistics, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland,
9 Department of Medicine, Division of Respirology, London Health Sciences Centre – Victoria Hospital,
Western University, London, Ontario, Canada, 10 Global Medical Affairs, Actelion Pharmaceuticals Ltd,
Allschwil, Switzerland, 11 Cardiopulmonary Department, Ignacio Chávez National Heart Institute, Mexico
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Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of
380–440 m may have improved prognosis. Using the randomized controlled trial of maciten-
tan in pulmonary arterial hypertension (SERAPHIN), the association between six-minute
walk distance and long-term outcomes was explored.
Methods
Patients with six-minute walk distance data at Month 6 were dichotomized as above or
below the median six-minute walk distance (400 m) and assessed for future risk of pulmo-
nary arterial hypertension-related death or hospitalization and all-cause death. Additionally,
six-minute walk distance values at baseline, Month 6 and the change from baseline to
Month 6 were categorized by quartiles. All associations were analyzed by the Kaplan–Meier
method using a log-rank test and Cox regression models.
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Results
Patients with a six-minute walk distance >400 m vs.400 m at Month 6 have a reduced risk
of pulmonary arterial hypertension-related death or hospitalization (hazard ratio 0.48; 95%
confidence interval 0.33–0.69). The risk was also lower for patients with higher quartiles of
six-minute walk distance at baseline or Month 6 (baseline: hazard ratio [Q4 (>430 m) vs. Q1
(300 m)] 0.23; 95% confidence interval 0.15–0.36; Month 6: hazard ratio [Q4 (>455 m) vs.
Q1 (348 m)] 0.33; 95% confidence interval 0.19–0.55). In contrast, six-minute walk dis-
tance changes at Month 6 were not associated with the risk of pulmonary arterial hyperten-
sion-related death or hospitalization (p = 0.477). These findings were consistent when
adjusted for known confounders. Similar results were observed for the risk of all-cause
death up to end of study.
Conclusions
Patients with pulmonary arterial hypertension walking >400 m had better long-term progno-
sis. Although changes in six-minute walk distance were not associated with long-term out-
comes, assessing absolute six-minute walk distance values remains important in the clinical
management of patients with pulmonary arterial hypertension.
Introduction
Pulmonary arterial hypertension (PAH) is a relentlessly progressive disease characterized by
an increase in pulmonary artery pressure and pulmonary vascular resistance, leading to right
ventricular failure and poor survival [1, 2]. As a consequence of the pulmonary hemodynamic
abnormalities, there is also a progressive decline in the functional and exercise capacity of
patients with PAH.
During recent decades, an important improvement in the management of PAH has been
witnessed through the development of targeted therapies that have a significant impact on
hemodynamics, exercise capacity and survival [3]. The efficacy of these therapies has been
assessed mainly in clinical trials by the short-term (3–6 months) improvement of exercise
capacity, measured by six-minute walk distance (6MWD) [3].
The 6MWD test is a simple and reproducible measure of exercise capacity, and, although
representing a submaximal level of functional capacity for most patients, has a close associa-
tion with a maximal cardiopulmonary exercise test [4]. Data from observational studies and
randomized trials suggest that absolute values of 6MWD are associated with better prognosis
[5–7], whereas short-term changes in 6MWD are not [6–10]. This is reflected in international
guidelines that describe treatment goals in PAH, in which a 6MWD value of greater than 380
m to 440 m is suggested to indicate response to therapy or better prognosis [11, 12].
Six-minute walking distance thresholds are commonly used in conjunction with other
clinical, functional and hemodynamic parameters when assessing and treating patients with
PAH. Several studies, using parameters outlined in the ESC/ERS guidelines, have shown that
patients at low risk have a better prognosis than patients stratified at high risk [13, 14]. Simi-
larly, a recent study in Japan demonstrated significantly better prognosis in patients with
6MWD >372 m, mean pulmonary arterial pressure46 mmHg and cardiac index>2.5 L/
min/m2 [15].
Six-minute walk distance and long-term outcomes in PAH
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The SERAPHIN study, with a median treatment duration of 2.2 years, was the first long-
term event-driven outcome trial in PAH [16]. As 6MWD was measured at baseline and at
Month 6, SERAPHIN provides a unique opportunity to analyze the association between
6MWD and long-term clinical outcomes in PAH.
Methods
Study design and patients
SERAPHIN was a multicenter, randomized controlled, event-driven study designed to assess
the long-term efficacy and safety of macitentan in patients with PAH (NCT00660179). The
study design has been described in detail elsewhere [17]. Briefly, patients were included if they
were 12 years of age or older and diagnosed by right heart catheterization with idiopathic
PAH, heritable PAH or PAH related to connective tissue disease, repaired congenital systemic
to pulmonary shunts, HIV infection, drug use or toxin exposure [16]. Patients had to be in
World Health Organization functional class (WHO FC) II–IV, achieve a baseline 6MWD of
50 m or more, and could be either treatment-naïve or receiving a stable dose of phosphodies-
terase type 5 inhibitors, oral or inhaled prostanoids, calcium channel blockers, or L-arginine
for at least 3 months prior to randomization. Patients receiving intravenous or subcutaneous
prostanoids and endothelin receptor antagonists were excluded. After screening, patients were
randomized (1:1:1) to placebo, macitentan 3 mg or macitentan 10 mg once daily. Treatment
was continued until a primary endpoint event of morbidity/mortality occurred, which indi-
cated the end of double-blind treatment (EOT), or until the end of study (EOS), which was
declared when the predefined target of 285 primary endpoint events had occurred, or earlier
in the case of premature double-blind treatment discontinuation [16]. Change in 6MWD from
baseline to Month 6, time to first occurrence of either PAH-related death or hospitalization up
to EOT, and time to all-cause death up to EOS were predefined secondary endpoints of the
study. Local institutional review boards or independent ethics committees approved the proto-
col. A full list of ethics committee/institutional review board(s) that approved the study is pro-
vided as supportive information (S1 Table). Written informed consent was obtained from all
patients before they entered the study. A special informed consent form was provided to
patients who are minors, in accordance with local regulations. A parent or legal representative
signed the consent on behalf of a minor. The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki.
Statistical analysis
To evaluate the association between 6MWD and long-term outcome, the risk for PAH-related
death or hospitalization up to EOT and for all-cause death up to EOS was calculated among:
1) patients with available 6MWD data at Month 6, dichotomized as above or below the median
6MWD value at Month 6 (400 m), or categorized by quartiles; 2) all randomized patients, cate-
gorized according to quartiles of 6MWD values at baseline; and 3) patients with available
6MWD data at baseline and Month 6, categorized according to quartiles of changes in 6MWD
at Month 6. Event-free Kaplan–Meier (K-M) estimates of PAH-related death or hospitalization
or all-cause death were determined for each categorization of 6MWD values and compared by
the log-rank test. Associations were analyzed using univariate Cox regression models and
expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). The validity of the pro-
portional hazards assumption was checked in the SERAPHIN study for the primary endpoint
of time to morbidity/mortality up to EOT using martingale-based residuals [18].
To account for potential confounding effects, the HRs were also adjusted for study treat-
ment, use of background PAH therapy at baseline and established prognostic markers of long-
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term outcome in PAH (age, sex, PAH etiology, and WHO FC) [2]. Interaction tests were
employed to evaluate potential heterogeneity across the treatment groups (placebo, macitentan
3 mg and macitentan 10 mg) with respect to the associations between 6MWD and long-term
outcome. As the p-values for interaction indicated no heterogeneity (S2 Table), the associa-
tions between 6MWD and long-term outcomes were therefore performed combining all study
treatment groups. As the objective was to determine the importance of a second measure of
6MWD on long-term outcome beyond Month 6, only patients with both baseline and Month
6 data were included in the analyses at Month 6. Patients who experienced an event under
investigation (PAH-related death or hospitalization, or all-cause death) prior to Month 6 were
excluded from these analyses. For the endpoint of PAH-related death or hospitalization up to
EOT, patients without an event were right censored at date of premature study drug discontin-
uation or date of last contact, date of end of study, or date of death for reasons not related to
PAH, whichever occurred first. For the endpoint of all-cause death up to EOS, patients without
an event were right censored at the end of study date (EOS visit date for completers or date of
premature study discontinuation/last contact for patients who did not complete the study as
scheduled).
Results
The 742 patients randomized in the SERAPHIN study were well-matched in terms of demo-
graphic, clinical, and disease characteristics at baseline. In total, 76.5% of patients were female,
mean (SD) age and time since diagnosis were 45.6 (16.1) years and 2.7 (4.0) years, respectively.
Mean (SD) 6MWD was 360 (100.2) meters, approximately half of patients were in WHO FC
I/II (52.5%) and WHO FC III/IV (47.5%) and background therapy included phosphodiesterase
type 5 inhibitor (61.4%) and oral or inhaled prostanoid therapy (5.4%) [16]. Three patients
had missing 6MWD values at baseline.
Association between 6MWD at Month 6 and long-term outcomes
In the analysis of the risk of PAH-related death or hospitalization, 298 patients had a 6MWD
400 m compared with 297 patients with a 6MWD >400 m at Month 6. The number of PAH-
related deaths or hospitalization events in these patients was 80 vs. 45, respectively. The risk of
experiencing an event was lower among patients with a 6MWD >400 m at Month 6 compared
with those with a 6MWD400 m (Fig 1A, Table 1).
There were 53 deaths among 325 patients who had a 6MWD400 m and 22 deaths among
300 patients who had a 6MWD >400 m at Month 6. Patients who achieved a 6MWD >400 m
at Month 6 had a significantly lower risk of all-cause death compared with those who were
below this value (Fig 1B, Table 2).
Patients with a 6MWD400 m at Month 6 had similar poor long-term outcome whether
they started above 400 m (n = 28) or below 400 m (n = 270) at baseline (adjusted HR 0.95; 95%
CI 0.38–2.38). In contrast, among patients with 6MWD >400 m at Month 6, those whose ini-
tial baseline 6MWD was below 400 m (n = 96) had a trend toward a higher risk of an event
compared with those that were above 400 m at baseline (n = 201; adjusted HR 1.79; 95% CI
0.98–3.25). Patients in the lowest 6MWD quartile at Month 6 (Q1) had a significantly higher
risk of experiencing an event compared with those in the other three quartiles (Fig 2A,
Table 1).
The effect of baseline 6MWD quartiles and long-term outcomes at Month 6 was consistent
with the observations for PAH-related death or hospitalization. Patients in the lowest 6MWD
quartile at Month 6 (Q1) had a significantly higher risk of death compared with those in the
other three quartiles (Fig 2B, Table 2).
Six-minute walk distance and long-term outcomes in PAH
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Association between 6MWD at baseline and long-term outcomes
The quartiles of 6MWD measured at baseline in the overall population were: Q1300 m
(n = 197); 300 m<Q2372 m (n = 179); 372 m<Q3430 m (n = 182) and Q4>430 m
(n = 181). In total, 199 patients (26.9%) experienced a PAH-related death or hospitalization
event up to EOT (81, 53, 40 and 25 for Q1 to Q4, respectively). Patients in Q1 had a signifi-
cantly higher risk of experiencing an event compared with those in the other three quartiles
(Fig 3A, Table 1).
For all-cause death, 126 (17.1%) events occurred up to EOS (62, 31, 22 and 11 for Q1 to Q4,
respectively). Similarly, patients in Q1 had a significantly higher risk of death compared with
those in the other three quartiles (Fig 3B, Table 2).
Association between changes in 6MWD at Month 6 and long-term outcomes
There were 595 patients with 6MWD values recorded at Month 6 who did not experience a
PAH-related death or hospitalization event prior to Month 6. The quartiles for the change in
Fig 1. Association between absolute 6MWD applying a cut-off of 400 m at Month 6 and long-term outcomes in
patients with PAH: A. PAH-related death or hospitalization up to end of treatment; B. All-cause death up to end
of study. 6MWD, six-minute walk distance; K-M, Kaplan–Meier; PAH, pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0193226.g001
Six-minute walk distance and long-term outcomes in PAH
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Table 1. Association between 6MWD and time to PAH-related death or hospitalization up to end of treatment.
6MWD assessment Categorization Number of PAH-related deaths or
hospitalizations / number of patients
Unadjusted hazard ratio (95%
CI) (vs. reference)
Adjusteda hazard ratio (95%
CI) (vs. reference)
Month 6 400 m; reference 80/298 – –






31/149 0.55 (0.35–0.87) 0.57 (0.36–0.92)
Q3 (>400−455
m)
25/151 0.40 (0.24–0.64) 0.41 (0.25–0.69)
Q4 (>455 m) 20/146 0.33 (0.19–0.55) 0.34 (0.20–0.60)





53/179 0.56 (0.39–0.79) 0.63 (0.44–0.90)
Q3 (>372−430
m)
40/182 0.39 (0.27–0.57) 0.43 (0.29–0.64)






Q2 (–9−20m) 32/156 1.02 (0.60–1.72) 1.02 (0.60–1.74)
Q3 (>20−57 m) 29/141 1.01 (0.59–1.73) 0.93 (0.54–1.60)
Q4 (>57 m) 39/145 1.37 (0.83–2.27) 1.19 (0.71–1.98)
aAdjusted for study treatment, use of background PAH therapy at baseline, age, sex, PAH etiology, and WHO FC.
6MWD, six-minute walk distance; CI, confidence interval; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class.
https://doi.org/10.1371/journal.pone.0193226.t001
Table 2. Association between 6MWD and time to all-cause death up to end of study.
6MWD assessment Categorization Number of deaths (all-cause) /
number of patients
Unadjusted hazard ratio (95% CI)
(vs. reference)
Adjusteda hazard ratio (95% CI)
(vs. reference)
Month 6 400 m; reference 53/325 – –




Q2 (>339−397 m) 19/158 0.53 (0.30–0.93) 0.49 (0.28–0.89)
Q3 (>397−452 m) 13/154 0.38 (0.20–0.71) 0.34 (0.17–0.68)
Q4 (>452 m) 9/156 0.27 (0.13–0.55) 0.24 (0.11–0.53)
Baseline Q1 (300 m;
reference)
62/197 – –
Q2 (>300−372 m) 31/179 0.50 (0.33–0.77) 0.56 (0.36–0.88)
Q3 (>372−430 m) 22/182 0.35 (0.21–0.56) 0.36 (0.21–0.60)
Q4 (>430 m) 11/181 0.18 (0.09–0.34) 0.18 (0.09–0.37)





Q2 (–10−19 m) 18/157 1.11 (0.56–2.17) 1.10 (0.56–2.18)
Q3 (>19−55 m) 18/153 1.13 (0.58–2.22) 0.97 (0.49–1.92)
Q4 (>55 m) 23/155 1.41 (0.75–2.68) 1.19 (0.62–2.29)
aAdjusted for study treatment, use of background PAH therapy at baseline, age, sex, PAH etiology, and WHO FC.
6MWD, six-minute walk distance; CI, confidence interval; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization functional class.
https://doi.org/10.1371/journal.pone.0193226.t002
Six-minute walk distance and long-term outcomes in PAH
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6MWD from baseline to Month 6 for these patients were: Q1–9 m (n = 153); –9 m>Q220
m (n = 156); 20 m>Q357 m (n = 141), and Q4>57 m (n = 145). The greatest changes in
6MWD were observed in patients with the lowest 6MWD at baseline (Fig 4A). The numbers
of PAH-related death or hospitalization events that occurred up to EOT were 25, 32, 29 and 39
for Q1 to Q4, respectively. There was no difference in the risk of experiencing an event
between the different quartiles (log-rank p = 0.477; Fig 4A, Table 1).
For the analysis on all-cause death, there were 625 patients with a 6MWD recorded at
Month 6. The quartiles for the change in 6MWD from baseline to Month 6 used to estimate
the risk of all-cause death were: Q1–10 m (n = 160); –10 m>Q219 m (n = 157); 19
m>Q355 m (n = 153) and Q4>55 m (n = 155). Again, the greatest changes in 6MWD were
observed in patients with the lowest 6MWD at baseline (Fig 4B). The number of deaths that
Fig 2. Association between absolute 6MWD quartiles at Month 6 and long-term outcomes in patients with PAH:
A. PAH-related death or hospitalization up to end of treatment; B. All-cause death up to end of study. 6MWD,
six-minute walk distance; K-M, Kaplan–Meier; PAH, pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0193226.g002
Six-minute walk distance and long-term outcomes in PAH
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occurred up to EOS was 16, 18, 18 and 23 for Q1 to Q4, respectively. There was no difference
in the risk of all-cause death between the different quartiles (log-rank p = 0.730; Fig 4B,
Table 2).
Discussion
SERAPHIN was the first prospective, long-term, randomized controlled study to assess disease
progression in more than 700 patients with PAH over a median treatment period of 2.2 years
[16]. Patients with a 6MWD of400 m at Month 6 were at reduced risk of future clinical
events, such as PAH-related death or hospitalization, and all-cause death. Patients with higher
absolute values of 6MWD at baseline or at Month 6 were confirmed as having better prognosis,
whereas the magnitude of change in 6MWD during this period was not associated with long-
term clinical outcomes.
Fig 3. Association between absolute 6MWD quartiles at baseline and long-term outcomes in patients with PAH:
A. PAH-related death or hospitalization up to end of treatment; B. All-cause death up to end of study. 6MWD,
six-minute walk distance; K-M, Kaplan–Meier; PAH, pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0193226.g003
Six-minute walk distance and long-term outcomes in PAH
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Since the study of Miyamoto et al. [5], it has been suggested that the evaluation of exercise
capacity at baseline, by the 6MWD test, could reflect prognosis in patients with PAH. Other
studies provided similar evidence regarding the prognostic value of the 6MWD test [6–8, 17,
19, 20]. Our study confirms that patients with greater 6MWD at baseline have a significantly
lower risk of disease progression, supporting the need for assessing 6MWD in daily clinical
practice, and that baseline 6MWD represents an important variable to consider in order to bet-
ter balance clinical study groups in randomized clinical trials.
Absolute 6MWD achieved following PAH treatment has been found to be associated with
long-term survival [6, 7, 17, 21]. Sitbon et al. [6], in a study evaluating 178 patients who used
intravenous epoprostenol as first-line therapy for PAH, demonstrated that patients who were
able to walk380 m after 3 months of PAH-specific therapy had better long-term survival.
Fig 4. Association between change in 6MWD from baseline to Month 6 (by quartiles) and long-term outcomes in
patients with PAH: A. PAH-related death or hospitalization up to end of treatment; B. All-cause death up to end
of study. 6MWD, six-minute walk distance; K-M, Kaplan–Meier; PAH, pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0193226.g004
Six-minute walk distance and long-term outcomes in PAH
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The same group has shown similar results in patients using first-line monotherapy with bosen-
tan [17]. A more recent study of 2716 patients with PAH enrolled in the US Registry to Evalu-
ate Early and Long-Term PAH Disease Management (REVEAL) found that, among other
variables, 6MWD440 m predicted increased survival at 1 year [21]. Based on these findings
and on clinical experience, a goal-oriented approach to treatment, which includes a target
6MWD of greater than 380–440 m, is recommended [11, 12]. In the SERAPHIN patient popu-
lation, when 400 m was applied as a cut-off at Month 6 (corresponding to the median 6MWD
at this time point), patients walking <400 m had twice the risk of PAH-related death or hospi-
talization and of all-cause death compared with those walking more than 400 m. These data
confirm the relevance of reassessing 6MWD following initiation of PAH-targeted therapy and
the usefulness of establishing absolute thresholds as treatment goals to be pursued in clinical
practice [12].
Improving survival would be the ultimate primary endpoint for a disease with high mortal-
ity rates. However, studies using survival as the primary endpoint would have a number of
caveats, such as the large sample size, long duration of the trial and the use of rescue therapies.
In order to reduce sample size and the duration of clinical trials, indirect outcome measures
are frequently used [22]. Improvement in 6MWD has been identified as one such indirect out-
come measure in PAH and has been used as the primary endpoint in many clinical trials [23,
24]. However, the clinical significance of the observed improvement in 6MWD has become a
matter of debate in recent years.
A sub-analysis of the Pulmonary Arterial Hypertension and Response to Tadalafil
(PHIRST) trial suggested that increases in 6MWD beyond 33 m would represent the minimal
important difference reflecting improved quality of life [25]. However, when looking at the
association with mortality, the Ambrisentan in Pulmonary Arterial Hypertension (ARIES) tri-
als indicated that, although an absolute 6MWD after 3 months of treatment was associated
with mortality, the change from baseline in 6MWD was not [7]. Furthermore, a meta-analysis
of 22 clinical trials in PAH demonstrated that changes in 6MWD did not predict improve-
ments in major clinical events in a short-term follow-up [9]. Another concurrent meta-analy-
sis of ten trials showed that the overall mean 6MWD improvement of 22.4 m accounted for
only a small proportion of the observed treatment effect on clinical events [26]. This suggests
that change in 6MWD did not represent a valid surrogate endpoint in PAH. Our study con-
firms that changes in 6MWD after 6 months are not associated with the long-term risk of
PAH-related death or hospitalization or with long-term survival. Moreover, patients with the
lowest 6MWD at baseline had the greatest increases in 6MWD after 6 months, but still had the
worst long-term outcomes. Although exercise capacity improved, the magnitude of the change
in 6MWD does not translate into improved long-term outcomes, unless a specific threshold is
obtained. These results do not support the use of change in 6MWD at 6 months as a prognostic
marker of long-term efficacy of any specific intervention in PAH. Clinically relevant endpoints
should be used to demonstrate improvement in long-term outcome.
Our study has limitations that should be acknowledged. This post hoc analysis included
only a subset of the SERAPHIN population, was not prospectively powered, and the statistical
analyses are exploratory in nature and should be interpreted with caution. The baseline charac-
teristics of this subset of the SERAPHIN population were similar to those of the overall SERA-
PHIN population and balanced between treatment arms. Although our analyses accounted for
differences in patient characteristics such as background PAH therapy at baseline, age, sex,
PAH etiology and WHO FC, a threshold of 400 m for 6MWD might be a conservative treat-
ment goal for a young patient with idiopathic PAH, or an unachievable goal for an older
patient, or for a patient with PAH associated with systemic sclerosis. Nevertheless, it is clear
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that achieving a functional status threshold, not the magnitude of improvement in exercise
capacity, should be the target when developing a treatment strategy.
Conclusions
In the SERAPHIN study, patients with PAH walking more than 400 m had a lower risk of dis-
ease progression, including PAH-related death or hospitalization and all-cause death.
Although changes in 6MWD were not associated with long-term outcome in patients with
PAH, assessing the absolute 6MWD values remains important in the clinical management of
patients with PAH.
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Gérald Simonneau.
Formal analysis: Franck-Olivier Le Brun.
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Writing – original draft: Rogério Souza, Franck-Olivier Le Brun, Loïc Perchenet.
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